FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157530349> ?p ?o ?g. }

• W3157530349 endingPage "924" @default.
• W3157530349 startingPage "914" @default.
• W3157530349 abstract "The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower-intensity regimens with clofarabine (n = 119) or cladribine (n = 129) combined with low-dose cytarabine (LDAC) alternating with decitabine. We reviewed response rates by subgroup and long term outcomes of 248 patients with newly diagnosed non core-binding-factor AML treated on two clinical trials investigating double nucleoside-analogue therapy (DNT) alternating with HMA from October, 2008 to April, 2018. Of 248 patients with a median age of 69 years (range, 49–85 years), 102 patients (41%) were ≥ 70 years, and 108 (44%) had adverse karyotype. Overall, 164 patients (66%) responded: 147 (59%) complete remission (CR) and 17 (7%) CR with incomplete count recovery (CRi). With a median follow up of 60 months, median relapse-free and overall survival (OS) were 10.8 and 12.5 months, respectively. The 2-year OS was 29%. Among patients with normal karyotype, the CR/CRi rate was 79% and the median OS 19.9 months. High response rates and OS were observed in patients with mutations in NPM1, FLT3, IDH2, and RUNX1. The 4- and 8-week mortality rates were 2% and 11%, respectively. The backbone of clofarabine or cladribine and LDAC alternating with decitabine was effective and safe for the treatment of older patients with newly diagnosed AML. Incorporating targeted therapies could extend the efficacy of this approach and provide more curative therapeutic options in this AML population." @default.
• W3157530349 created "2021-05-10" @default.
• W3157530349 creator A5000750846 @default.
• W3157530349 creator A5016368595 @default.
• W3157530349 creator A5020340537 @default.
• W3157530349 creator A5021380291 @default.
• W3157530349 creator A5028845635 @default.
• W3157530349 creator A5030500582 @default.
• W3157530349 creator A5035605515 @default.
• W3157530349 creator A5046135731 @default.
• W3157530349 creator A5049385583 @default.
• W3157530349 creator A5050975340 @default.
• W3157530349 creator A5055045706 @default.
• W3157530349 creator A5057822243 @default.
• W3157530349 creator A5058755419 @default.
• W3157530349 creator A5059373442 @default.
• W3157530349 creator A5061026876 @default.
• W3157530349 creator A5066894053 @default.
• W3157530349 creator A5069176297 @default.
• W3157530349 creator A5084290698 @default.
• W3157530349 creator A5085521139 @default.
• W3157530349 creator A5088307376 @default.
• W3157530349 creator A5090435894 @default.
• W3157530349 date "2021-05-26" @default.
• W3157530349 modified "2023-10-15" @default.
• W3157530349 title "Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia" @default.
• W3157530349 cites W1556454749 @default.
• W3157530349 cites W1569756545 @default.
• W3157530349 cites W1572539757 @default.
• W3157530349 cites W1585096943 @default.
• W3157530349 cites W1600365609 @default.
• W3157530349 cites W1857665725 @default.
• W3157530349 cites W1969474912 @default.
• W3157530349 cites W1978496616 @default.
• W3157530349 cites W2007386979 @default.
• W3157530349 cites W2013923593 @default.
• W3157530349 cites W2035543326 @default.
• W3157530349 cites W2047154542 @default.
• W3157530349 cites W2051987542 @default.
• W3157530349 cites W2058188142 @default.
• W3157530349 cites W2073101822 @default.
• W3157530349 cites W2079025304 @default.
• W3157530349 cites W2100883771 @default.
• W3157530349 cites W2106084333 @default.
• W3157530349 cites W2108718836 @default.
• W3157530349 cites W2110893339 @default.
• W3157530349 cites W2114441791 @default.
• W3157530349 cites W2149058047 @default.
• W3157530349 cites W2160968219 @default.
• W3157530349 cites W2162806047 @default.
• W3157530349 cites W2288894655 @default.
• W3157530349 cites W2527290204 @default.
• W3157530349 cites W2559537906 @default.
• W3157530349 cites W2738685991 @default.
• W3157530349 cites W2883399820 @default.
• W3157530349 cites W2886917823 @default.
• W3157530349 cites W2898284215 @default.
• W3157530349 cites W2922287868 @default.
• W3157530349 cites W2922547112 @default.
• W3157530349 cites W2946108656 @default.
• W3157530349 cites W2946403475 @default.
• W3157530349 cites W2953094268 @default.
• W3157530349 cites W2969998705 @default.
• W3157530349 cites W3007376421 @default.
• W3157530349 cites W3021226340 @default.
• W3157530349 cites W3048827006 @default.
• W3157530349 cites W3080935763 @default.
• W3157530349 cites W3083003645 @default.
• W3157530349 cites W3094566369 @default.
• W3157530349 cites W3107627007 @default.
• W3157530349 cites W3128937923 @default.
• W3157530349 cites W3144004041 @default.
• W3157530349 doi "https://doi.org/10.1002/ajh.26206" @default.
• W3157530349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33901324" @default.
• W3157530349 hasPublicationYear "2021" @default.
• W3157530349 type Work @default.
• W3157530349 sameAs 3157530349 @default.
• W3157530349 citedByCount "10" @default.
• W3157530349 countsByYear W31575303492021 @default.
• W3157530349 countsByYear W31575303492022 @default.
• W3157530349 countsByYear W31575303492023 @default.
• W3157530349 crossrefType "journal-article" @default.
• W3157530349 hasAuthorship W3157530349A5000750846 @default.
• W3157530349 hasAuthorship W3157530349A5016368595 @default.
• W3157530349 hasAuthorship W3157530349A5020340537 @default.
• W3157530349 hasAuthorship W3157530349A5021380291 @default.
• W3157530349 hasAuthorship W3157530349A5028845635 @default.
• W3157530349 hasAuthorship W3157530349A5030500582 @default.
• W3157530349 hasAuthorship W3157530349A5035605515 @default.
• W3157530349 hasAuthorship W3157530349A5046135731 @default.
• W3157530349 hasAuthorship W3157530349A5049385583 @default.
• W3157530349 hasAuthorship W3157530349A5050975340 @default.
• W3157530349 hasAuthorship W3157530349A5055045706 @default.
• W3157530349 hasAuthorship W3157530349A5057822243 @default.
• W3157530349 hasAuthorship W3157530349A5058755419 @default.
• W3157530349 hasAuthorship W3157530349A5059373442 @default.
• W3157530349 hasAuthorship W3157530349A5061026876 @default.
• W3157530349 hasAuthorship W3157530349A5066894053 @default.

• next